Stockreport

Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patien...

Actinium Pharmaceuticals, Inc. (Delaware)  (ATNM) 
NASDAQ:AMEX Investor Relations: ir.actiniumpharma.com
PDF Expansion into frontline setting greatly expands potential addressable patient opportunity for Actimab-A Triplet combination supported by previously completed Phase 1 [Read more]